INVO BIOSCIENCE, INC. Financials INVO Bioscience, Inc.
Equities
INVO
US44984F4019
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9143 USD | -1.58% |
|
-18.37% | -32.27% |
| Apr. 18 | Top Premarket Decliners | MT |
| Apr. 17 | Sector Update: Health Care Stocks Retreating Late Afternoon | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 64.45 | 33.8 | 28.78 | 39.08 | 5.156 | 3.341 |
| Enterprise Value (EV) 1 | 64.63 | 33.01 | 19.46 | 35.52 | 7.73 | 11.79 |
| P/E ratio | -20.1 x | -15.5 x | -1.98 x | -5.29 x | -0.47 x | -0.26 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 130 x | 22.8 x | 27.7 x | 9.39 x | 6.27 x | 1.11 x |
| EV / Revenue | 131 x | 22.3 x | 18.8 x | 8.54 x | 9.4 x | 3.9 x |
| EV / EBITDA | -58.8 x | -19.6 x | -3.54 x | -6.84 x | -0.73 x | -1.8 x |
| EV / FCF | -101 x | -14.8 x | -18.2 x | -30.6 x | -3.07 x | 18.4 x |
| FCF Yield | -0.99% | -6.76% | -5.5% | -3.27% | -32.5% | 5.44% |
| Price to Book | -23.8 x | -9.1 x | 5.05 x | 5.43 x | -5.28 x | -0.66 x |
| Nbr of stocks (in thousands) | 240 | 244 | 478 | 587 | 608 | 2,475 |
| Reference price 2 | 268.8 | 138.4 | 60.20 | 66.60 | 8.476 | 1.350 |
| Announcement Date | 4/16/19 | 3/30/20 | 3/30/21 | 3/31/22 | 4/17/23 | 4/16/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.4944 | 1.48 | 1.037 | 4.16 | 0.8222 | 3.021 |
| EBITDA 1 | -1.099 | -1.684 | -5.503 | -5.189 | -10.55 | -6.566 |
| EBIT 1 | -1.104 | -1.694 | -5.515 | -5.217 | -10.63 | -6.767 |
| Operating Margin | -223.32% | -114.47% | -531.67% | -125.39% | -1,292.45% | -224.04% |
| Earnings before Tax (EBT) 1 | -3.076 | -2.167 | -8.347 | -6.65 | -10.89 | -8.007 |
| Net income 1 | -3.076 | -2.168 | -8.347 | -6.655 | -10.89 | -8.035 |
| Net margin | -622.22% | -146.43% | -804.73% | -159.97% | -1,324.81% | -266% |
| EPS 2 | -13.36 | -8.929 | -30.41 | -12.60 | -18.00 | -5.131 |
| Free Cash Flow 1 | -0.6419 | -2.233 | -1.071 | -1.16 | -2.514 | 0.6415 |
| FCF margin | -129.84% | -150.84% | -103.25% | -27.89% | -305.75% | 21.24% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/16/19 | 3/30/20 | 3/30/21 | 3/31/22 | 4/17/23 | 4/16/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.048 | 0.1626 | 0.1461 | 0.2353 | 0.2781 | 0.348 | 0.3159 | 0.9749 | 1.382 | 1.576 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 0.5036 | -2.701 | -2.682 | -2.525 | -2.718 | -2.306 | -2.066 | -0.8863 | -1.508 | -0.9464 |
| Operating Margin | 16.52% | -1,661.09% | -1,835.1% | -1,073.19% | -977.31% | -662.71% | -654% | -90.91% | -109.17% | -60.04% |
| Earnings before Tax (EBT) 1 | 0.1018 | -2.774 | -2.801 | -2.55 | -2.765 | -2.551 | -2.238 | -1.247 | -1.972 | -1.595 |
| Net income 1 | -0.1415 | -2.774 | -2.802 | -2.55 | -2.767 | -2.551 | -2.241 | -1.248 | -1.995 | -1.597 |
| Net margin | -4.64% | -1,706.22% | -1,917.02% | -1,083.47% | -994.84% | -732.95% | -709.25% | -128.06% | -144.37% | -101.28% |
| EPS | -0.4000 | -4.600 | -4.600 | -4.200 | -4.600 | -4.000 | -3.060 | -0.7000 | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/31/22 | 5/16/22 | 8/15/22 | 11/14/22 | 4/17/23 | 5/15/23 | 8/14/23 | 11/13/23 | 4/16/24 | 5/15/24 |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.18 | - | - | - | 2.57 | 8.45 |
| Net Cash position 1 | - | 0.78 | 9.32 | 3.56 | - | - |
| Leverage (Debt/EBITDA) | -0.1669 x | - | - | - | -0.244 x | -1.287 x |
| Free Cash Flow 1 | -0.64 | -2.23 | -1.07 | -1.16 | -2.51 | 0.64 |
| ROE (net income / shareholders' equity) | 79.7% | 67.3% | -823% | -102% | -344% | 18,953% |
| ROA (Net income/ Total Assets) | -132% | -82.3% | -54.1% | -30.5% | -91.2% | -33.8% |
| Assets 1 | 2.326 | 2.633 | 15.43 | 21.85 | 11.95 | 23.74 |
| Book Value Per Share 2 | -11.30 | -15.20 | 11.90 | 12.30 | -1.610 | -2.050 |
| Cash Flow per Share 2 | 0.8800 | 5.070 | 21.00 | 9.530 | 0.1500 | 0.0900 |
| Capex 1 | 0.02 | 0.11 | 0.05 | 0.42 | 0.01 | 0.44 |
| Capex / Sales | 3.92% | 7.75% | 4.75% | 9.99% | 1.31% | 14.72% |
| Announcement Date | 4/16/19 | 3/30/20 | 3/30/21 | 3/31/22 | 4/17/23 | 4/16/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
Number of Analysts
0
Last Close Price
0.9143
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -32.27% | 2.55M | |
| -6.46% | 180B | |
| +3.39% | 112B | |
| -3.68% | 68.53B | |
| +5.44% | 51.97B | |
| +5.70% | 44.08B | |
| +4.37% | 42.23B | |
| +25.42% | 32.43B | |
| +14.52% | 26.39B | |
| -4.29% | 24.97B |
- Stock Market
- Equities
- INVO Stock
- Financials INVO Bioscience, Inc.